Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06548763
PHASE2

Oral Topotecan With Toripalimab for Patients With Endometrial Cancer

Sponsor: Fudan University

View on ClinicalTrials.gov

Summary

This study aims to explore the safety and efficacy of oral topotecan combined with toripalimab in treating advanced/recurrent endometrial cancer through a single-center, prospective, single-arm, phase II clinical trial. The goal is to explore the first-line treatment options for endometrial cancer patients in the era of immunotherapy, to improve the overall treatment level and prognosis of endometrial cancer.

Official title: Oral Topotecan in Combination With Toripalimab for Patients With Advanced/Recurrent Endometrial Cancer: a Phase II Clinical Study

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2024-11-30

Completion Date

2026-12-31

Last Updated

2024-08-12

Healthy Volunteers

No

Interventions

DRUG

Topotecan

1.4mg/㎡, orally administered, d1-5

DRUG

Toripalimab

240mg, intravenous drip, d1, q3w

Locations (1)

Fudan university shanghai cancer center, Deparment of gynecologic oncology

Shanghai, Shanghai Municipality, China